CEO Presentation Half Year Results to 31 December 2025

• On track to achieve full-year earnings guidance
• Strong revenue growth including 5% organic growth
• EPS improving and return on invested capital a top priority
• EBITDA margin enhancement for majority of the business
• Ongoing focus on cost control across the business

Sonic Healthcare has reported strong H1 FY 2026 results, with revenue growth of 17% and EBITDA growth of 10%. The company is on track to achieve its full-year earnings guidance, with EBITDA guidance maintained at A$1.87 - A$1.95 billion (constant currency). Sonic demonstrated operating leverage and synergy realisation through EBITDA margin enhancement for the majority of the business, despite some dilution from acquisitions and restructuring costs in the USA. The company remains focused on cost control across the business and is progressing capital management initiatives, including sale and leaseback transactions and a potential share buyback. Sonic's diverse global portfolio of medical practices, leading market positions, and attractive growth opportunities in existing markets position the company well for the future.

EBITDA guidance maintained at A$1.87 - A$1.95 billion (constant currency) for FY 2026. Depreciation expense forecast at A$770 - $780 million (constant currency), interest expense to increase by ~15% (constant currency) versus prior year, and effective tax rate expected to be ~27%.

Sonic Healthcare remains focused on executing its strategic priorities, including maintaining a strong balance sheet, progressive dividends, selective synergistic acquisitions, and capital management initiatives to drive shareholder value.